Multidrug-resistant tuberculosis

doi:10.1038/s41572-024-00504-2

Multidrug-resistant tuberculosis

2024-03-24

27

OA

AI

Daniela María Cirillo

DOI：10.1038/s41572-024-00504-2

Original

Original request for help

Save

Abstract

En 中文

Tuberculosis (TB) remains the foremost cause of death by an infectious disease globally. Multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB; resistance to rifampicin and isoniazid, or rifampicin alone) is a burgeoning public health challenge in several parts of the world, and especially Eastern Europe, Russia, Asia and sub-Saharan Africa. Pre-extensively drug-resistant TB (pre-XDR-TB) refers to MDR/RR-TB that is also resistant to a fluoroquinolone, and extensively drug-resistant TB (XDR-TB) isolates are additionally resistant to other key drugs such as bedaquiline and/or linezolid. Collectively, these subgroups are referred to as drug-resistant TB (DR-TB). All forms of DR-TB can be as transmissible as rifampicin-susceptible TB; however, it is more difficult to diagnose, is associated with higher mortality and morbidity, and higher rates of post-TB lung damage. The various forms of DR-TB often consume >50% of national TB budgets despite comprising <5-10% of the total TB case-load. The past decade has seen a dramatic change in the DR-TB treatment landscape with the introduction of new diagnostics and therapeutic agents. However, there is limited guidance on understanding and managing various aspects of this complex entity, including the pathogenesis, transmission, diagnosis, management and prevention of MDR-TB and XDR-TB, especially at the primary care physician level.

Keywords:

ACQUIRED DRUG-RESISTANCE

DOSE-RANGING TRIAL

MYCOBACTERIUM-TUBERCULOSIS

TREATMENT OUTCOMES

PULMONARY TUBERCULOSIS

LOPINAVIR-RITONAVIR

TREATMENT REGIMENS

RISK-FACTORS

BEDAQUILINE

IMPACT

Multidrug-resistant tuberculosis

Abstract

Journal

Organization